Abstract
Background: Regulatory T-Cells (Treg Cells), as one of the immune system components, have been highly effective in the autoimmune diseases prevention, particularly multiple sclerosis (MS). Cytokine-based therapies such as interferon beta-1a (IFN-β1a) is a common drug in MS treatment; however, its exact mechanisms are insufficiently described.
Objective: Therefore, the goal of this study was to evaluate the in vivo impact of IFN-β1a on the Treg Cells in MS.
Methods: In this case-control study, Treg Cells were analysed by flowcytometry in IFN-β1a-treated relapsing-remitting MS (RRMS) in comparison with new cases of MS and healthy subjects.
Results: The frequency of Treg Cells in the IFN-β1a treated-RRMS was increased compared to the new MS cases (P < 0.05). Furthermore, the MFIs of the CD4 and CD25 in T-Cells were significantly reduced in new cases of MS and IFN-β1a-treated RRMS than the control subjects (P < 0.05). Additionally, the FoxP3 MFIs in CD4 + CD25 + T-Cells of IFN-β1a-treated RRMS were significantly lower than the new cases of MS.
Conclusion: Overall, the present study indicated that IFN-β1a as an immunomodulatory drug led to an enhancement in Treg Cells population without CD4, CD25, and FoxP3 molecules upregulation in Treg Cells.
Keywords: Interferon beta-1a, multiple sclerosis, regulatory T-cells, myelin, sheath, CNS, Treg cells.
CNS & Neurological Disorders - Drug Targets
Title:Characterization of Regulatory T-Cells in Multiple Sclerosis Patients Treated with Interferon Beta-1a
Volume: 17 Issue: 2
Author(s): Mohsen Ebrahimimonfared, Ali Ganji, Sara Zahedi, Parisa Nourbakhsh, Keyvan Ghasami and Ghasem Mosayebi*
Affiliation:
- Molecular and Medicine Research Center, Arak University of Medical Sciences, Arak,Iran
Keywords: Interferon beta-1a, multiple sclerosis, regulatory T-cells, myelin, sheath, CNS, Treg cells.
Abstract: Background: Regulatory T-Cells (Treg Cells), as one of the immune system components, have been highly effective in the autoimmune diseases prevention, particularly multiple sclerosis (MS). Cytokine-based therapies such as interferon beta-1a (IFN-β1a) is a common drug in MS treatment; however, its exact mechanisms are insufficiently described.
Objective: Therefore, the goal of this study was to evaluate the in vivo impact of IFN-β1a on the Treg Cells in MS.
Methods: In this case-control study, Treg Cells were analysed by flowcytometry in IFN-β1a-treated relapsing-remitting MS (RRMS) in comparison with new cases of MS and healthy subjects.
Results: The frequency of Treg Cells in the IFN-β1a treated-RRMS was increased compared to the new MS cases (P < 0.05). Furthermore, the MFIs of the CD4 and CD25 in T-Cells were significantly reduced in new cases of MS and IFN-β1a-treated RRMS than the control subjects (P < 0.05). Additionally, the FoxP3 MFIs in CD4 + CD25 + T-Cells of IFN-β1a-treated RRMS were significantly lower than the new cases of MS.
Conclusion: Overall, the present study indicated that IFN-β1a as an immunomodulatory drug led to an enhancement in Treg Cells population without CD4, CD25, and FoxP3 molecules upregulation in Treg Cells.
Export Options
About this article
Cite this article as:
Ebrahimimonfared Mohsen , Ganji Ali , Zahedi Sara, Nourbakhsh Parisa , Ghasami Keyvan and Mosayebi Ghasem *, Characterization of Regulatory T-Cells in Multiple Sclerosis Patients Treated with Interferon Beta-1a, CNS & Neurological Disorders - Drug Targets 2018; 17 (2) . https://dx.doi.org/10.2174/1871527317666180327122435
DOI https://dx.doi.org/10.2174/1871527317666180327122435 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Sexual Dimorphism in Autoimmune Disease
Current Molecular Medicine Role of Renin-Angiotensin System in Inflammation, Immunity and Aging
Current Pharmaceutical Design Molecular Genetics and Epidemiology of Japanese Type 1 Diabetes
Current Pharmacogenomics Combinatorial Application of Multiple High-throughput Biotechnologies for the Study of Autoimmune Diseases
Current Pharmaceutical Analysis Anti-TNF-α Antibody Therapies in Autoimmune Diseases
Current Topics in Medicinal Chemistry α-Galactosylceramide: Potential Immunomodulatory Activity and Future Application [General Articles]
Current Medicinal Chemistry Human Fetal Mesenchymal Stem Cells
Current Stem Cell Research & Therapy Discovery of Potent Bruton’s Tyrosine Kinase Inhibitors Using Ligand Based Modeling
Anti-Cancer Agents in Medicinal Chemistry The HLA Region and Autoimmune Disease: Associations and Mechanisms of Action
Current Genomics Recent Advances in Improving Sub-Unit Vaccine Efficacy Using Cytokines as more Specific Immune Inducing Adjuvants
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry The Neuropeptides VIP / PACAP and T Cells: Inhibitors or Activators?
Current Pharmaceutical Design Monoclonal Antibody-based Genetic Immunotherapy
Current Gene Therapy Are B Cells a Potential Target for Therapeutic Intervention in the Classical T Cell-Mediated Autoimmune Disease Type 1 Diabetes?
Inflammation & Allergy - Drug Targets (Discontinued) Antioxidant Therapy for Prevention of Inflammation, Ischemic Reperfusion Injuries and Allograft Rejection
Cardiovascular & Hematological Agents in Medicinal Chemistry Pharmacogenomics of Methotrexate: Current Status and Future Outlook
Current Drug Metabolism Monoclonal Antibodies: New Therapeutic Agents for Autoimmune Hemolytic Anemia?
Endocrine, Metabolic & Immune Disorders - Drug Targets Endothelial Expression of MHC Class II Molecules in Autoimmune Disease
Current Pharmaceutical Design Recent Clinical Trials of Cladribine in Hematological Malignancies and Autoimmune Disorders
Reviews on Recent Clinical Trials Protein Tyrosine Phosphatase as Potential Therapeutic Target in various Disorders
Current Molecular Pharmacology Cannabinoids, Immune System and Cytokine Network
Current Pharmaceutical Design